Skip to content

A comparative study on the clinical efficacy of different hyperbaric oxygen treatment regimens in patients with cerebral hemorrhage

A comparative study on the clinical efficacy of different hyperbaric oxygen treatment regimens in patients with cerebral hemorrhage

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100051417
Enrollment
Unknown
Registered
2021-09-23
Start date
2021-10-01
Completion date
Unknown
Last updated
2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral hemorrhage

Interventions

Normal control group:None
Cerebral hemorrhage group:Intracranial hematoma removal
1.6 ATA hyperbaric oxygen therapy group:1.6 ATA hyperbaric oxygen therapy
2.4 ATA hyperbaric oxygen therapy group:2.4 ATA hyperbaric oxygen therapy

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients Age >=18 years old; 2.The diagnosis meets the diagnostic criteria for hypertensive cerebral hemorrhage revised by the Fourth Cerebrovascular Disease Conference of China; 3.CT imaging examination supports the diagnosis of cerebral hemorrhage; 4.Have indications for intracerebral hemorrhage surgery; 5.The first onset, and the onset time at admission8 points; 6.Stable vital signs.

Exclusion criteria

Exclusion criteria: 1.Severe heart, liver, kidney and other organ dysfunction; 2.Combined with infectious diseases of the respiratory system or other infectious diseases; 3.Cerebral hemorrhage secondary to arteriovenous malformation, intracranial aneurysm or tumor; 4.Cancer, autoimmune disease, bleeding tendency disease; 5.Have a history of stroke and other neurological diseases; 6.Subarachnoid hemorrhage, primary ventricular hemorrhage, drug-induced hemorrhagic stroke.

Design outcomes

Primary

MeasureTime frame
Glasgow coma score;Neuron-specific enolase;Tumor necrosis factor-a;C reactive protein;

Secondary

MeasureTime frame
Transcranial doppler examination;Interleukin-1ß;Interleukin-6;

Countries

China

Contacts

Public ContactWang Haitao

Shanghai Sixth People's Hospital

bananawht@163.com+86 13817057783

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026